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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of newly diagnosed large cell
non-Hodgkin’s lymphoma
Incidence
. Large Cell Lymphoma constitutes 30–58% of non-Hodg-
kin’s lymphoma series. The crude incidence in the European
Union is 3–4/100 000 per year. The incidence increases
with age from 0.3/100 000 per year (35–39 y) to
26.6/100 000 per year (80–84 y).
Diagnosis
. Diagnosis should almost always be based on a surgical
specimen/excisional lymph node biopsy providing enough
material for fresh frozen and formalin-fixed samples. To
ensure adequate quality, immediate processing by an experi-
enced pathology institute has to be guaranteed.
. Fine needle aspirations or core biopsies may be appropriate
as the only diagnostic test in the rare patients requiring
emergency treatment or those not suitable for curative
therapy.
. The histological report should give the diagnosis according
to the WHO classification with use of CD20
immunohistochemistry.
Staging and risk assessment
. Patients amenable to curative therapy should have at least a
chest X-ray and a CT-scan of the abdomen, as well as a
bone marrow aspirate and biopsy. A diagnostic spinal tap
directly combined with a first prophylactic instillation of
cytarabine or methotrexate shall be considered in high-risk
patients [patients with more than two adverse parameters
according to international prognostic index (IPI)] with e.g.
involvement of bone marrow, testis, the spine, or the base
of the skull [V, D].
. A complete blood count, routine blood chemistry including
LDH and uric acid as well as a screening test for HIV and
hepatitis B and C are required. Protein electrophoresis is
recommended for B-cell lymphomas.
. The staging is given according to the Ann Arbor system
with mentioning of bulky disease [III, A]. For prognostic
purposes, the IPI should be established [III, A].
Treatment plan
. A multidisciplinary treatment planning is required:
Treatment with curative intent: CHOP-treatment combined
with rituximab given every 21 days for usually 8 cycles is
the current standard for CD20 + large-cell non-Hodgkin’s
lymphoma of all stages [II, A]. In T-cell lymphoma, CHOP
remains the standard. Shortening the interval between
CHOP cycles to two weeks with growth factor support may
be considered [II, B].
. High-dose chemotherapy with stem cell transplantation in
poor risk patients remains experimental.
. Consolidation by radiotherapy to sites of bulky disease has
not proven its benefit [III, C].
. Dose reductions due to hematological toxicity should be
avoided and febrile neutropenia justifies prophylactic use of
hematopoietic growth factors in patients treated with cura-
tive intent.
Response evaluation
. Adequate radiological tests should be done after 2 to 4
cycles and after the last cycle of CHOP or CHOP + radio-
therapy, and whenever there are doubts regarding adequate
response.
. An initially pathologic bone marrow aspirate/biopsy or
spinal tap should be repeated at the end of treatment.
. Patients with incomplete or lacking response should be eval-
uated for early salvage regimens.
Follow-up
. History and physical examination every 3 months for 2
years, every 6 months for 3 more years, and then once a year
with attention to development of secondary tumors [V, D].
High-risk patients still with curative options, such as
high-dose chemotherapy with stem cell support, may
mandate more frequent controls.
. Blood count and LDH at 3, 6, 12, and 24 months, then only
as needed for evaluation of suspicious symptoms or clinical
findings in those patients suitable for further therapy [V, D].
. Evaluation of thyroid dysfunction (TSH) in patients with
irradiation to the neck at 1, 2, and at least at 5 years [III,
A].
. After having received chest irradiation at premenopausal
age, especially at an age below 25 years, women should be
screened for secondary breast cancers clinically [III, A] and,
after the age of 40–50 years, by mammography [III, C].
. Minimal adequate radiological examinations at 6, 12, and
24 months after end of treatment, by CT scan when indi-
cated by site of disease [V, D].
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Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
Literature
1. Harris NL, Jaffe ES, Stein H et al. A revised European-American
classification of lymphoid neoplasms: a proposal from the Inter-
national Lymphoma Study Group. Blood 1994; 84: 1361–1392.
2. Smithers DW. Summary of papers delivered at the Conference on Sta-
ging in Hodgkin’s Disease (Ann Arbor). Cancer Res 1971; 31:
1869–1870.
3. Shipp M, Harrington D, Anderson J et al. A predictive model
for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329:
987–994.
4. Cheson BD, Horning SJ, Coiffier B. Report of an international work-
shop to standardize response criteria for Non-Hodgkin’s lymphomas.
J Clin Oncol 1999; 17: 1244–1253.
5. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard
regimen (CHOP) with three intensive chemotherapy regimens for
advanced non-Hodgkin’s lymphoma. N Engl J Med 1993; 328:
1002–1006.
6. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone com-
pared with chemotherapy plus radiotherapy for localized intermediate-
and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998; 339:
21–26.
7. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituxi-
mab compared with CHOP alone in elderly patients with diffuse
large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.
8. Pfreundschuh M, Trumper L, Kloess M et al. German High-Grade
Non-Hodgkin’s Lymphoma Study Group. Two-weekly or 3-weekly
CHOP chemotherapy with or without etoposide for the treatment
of elderly patients with aggressive lymphomas: results of the
NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641.
9. Pfreundschuh MG, Trumper L, Ma D et al. Randomized intergroup
trial of first line treatment for patients < = 60 years with diffuse large
B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like
regimen with or without the anti-CD20 santibody rituximab—early
stopping after the first interim analysis. J Clin Oncol 2004; 22(14S):
(Abstr. 6500).
Coordinating authors for the ESMO Guidelines Task Force: L. M. Jost1,
O. Kloke2 & R. A. Stahel3
1Invited author and member of the task force, Oncology, Kantonsspital,
CH-4101 Bruderholz/BL, Switzerland; 2Assigned task force member,
Elisabeth Krankenhaus GmbH, Abt. Onkologie/Ha¨matologie,
Ro¨ntgenstrasse 10, 45661 Recklinghausen, Germany; 3Assigned task force
member, Division of Oncology, University Hospital, Ra¨mistrasse 100,
CH-8091 Zu¨rich, Switzerland
Approved by the ESMO Guidelines Task Force: February 2002, last
update December 2004.
Correspondence to:
ESMO Guidelines Task Force
ESMO Head Office
Via La Santa 7
CH-6962 Lugano
Switzerland
i59
